Boehringer invests 61 million in the global 'hubs' of Sant Cugat

The multinational Boehringer Ingelheim will allocate 61 million euros this year to thehubsdigital and technological that from Sant Cugat del Vallès provide various services to the entire pharmaceutical group. The resources, whichadd to the more than 100 million that these centers have received in the last four years, the teams working on them will be strengthened, and the functions carried out will be expanded. Currently, both areas comprise more than 270 workers, to whom another sixty professionals from various specialties will be added by the end of 2022.Created in 2018, the Delivery Unit hub that supports drug promotionhas focused its efforts on developing innovative projects aimed at the continuous improvement of Boehringer Ingelheim in areas such as automation and campaign measurement, digital asset management, and data integration and learning management services. In its four years of operation, and given the results obtained,services related to digital performance, web measurement and personalization, search enablement and optimization, and medical operations have been added

For this reason, in this innovation plot, the German pharmaceutical company has invested 10 million since it established it in Catalonia and will consolidate it with 11 million euros this year. It also plans to double this investment in the next two years.

To date, the priority was to establish ahubof Digital Marketing and another ofGlobal Analytics andData Qualitythat would provide strategic digital service to the entire Boehringer Ingelheim group, both for human health and animal health businesses. However, it stands out from the new functions that are intended to be entrusted to him that this yearthe center is developing a medical affairs team that focuses on publications management, with the aim of optimizing clinical data communication for the healthcare sector. In 2023, medical specialists will join this team in generating reports ofReal World Evidence, as well as acall centeron clinical data articles that will serve globally. The company's management foresees that thishubincrease the number of collaborators from 39 to 47 throughout this year and reacha staff of 160 people in 2025.In the teams, 10 different nationalities are represented, 53% of the workers are women, and the staff's ages range between 26 and 50 years old.

The technology center will create a medical affairs team for publication management, in order to optimize the communication of clinical data for the healthcare sector.

"The ambition that the company pursues with thehubdigital it has in Spain is to become a digital leader within the pharmaceutical industry and establish itself as a strategic center worldwide. This team has been created to optimize the experience of our patients and clients. For this reason, we are committed to the best talent, offer opportunities for professional growth and development, as well as a hybrid and reconciliation environment, and invest each year in new projects," assures Rosa María López, Head of Business Operations at Boehringer Ingelheim Spain. Regarding the other center of international operations,the IT Service Center was launched in 2013 and has 250 professionals, which will increase to 300 by the end of 2022, according to the multinational's forecasts.This development area will receive 50 million euros in 2022, a figure 10% higher than the 45 million invested in 2021 and 25% more than the 40 million in 2020.This global area offers three strategic service lines worldwide.The highlight is that it operates in the field of cybersecurity.It is the center responsible for the acquisition and analysis of information to identify, track, and predict cyber capabilities, intentions, and activities that support Boehringer's business in decision-making. This way, they are secured against possible cyberattacks.

The digital hub has specialized in cybersecurity and industry 4.0 technologies

Likewise, it is responsible for applying new industry 4.0 technologies to achieve the most advanced level of automation in Boehringer Ingelheim's global drug production plants. And, finally, it also assumes global control of the computing, transmission, or telecommunication networks of Boehringer Ingelheim's different offices and plants. Established in Spain since 1952, the German group has two international production centers and its corporate headquarters for all of Spain in Sant Cugat, with a global workforce of 1,900 employees in the country.In 2021, the Boehringer Ingelheim group worldwide increased its revenues by 5.4%with net sales of 20.6 billion euros, a figure that was completed with 4.1 billion euros in R&D investments.

Add The New Barcelona Post as your preferred Google source for free

Stay informed with the latest news.

Activate now